New eye scanner software could sharpen diagnosis of macular degeneration

NCT ID NCT02827071

Terminated Diagnosis Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new software called AngioScan, used with an already-approved eye camera, to see if it can take better pictures of the back of the eye. Researchers looked at 150 patients with retinal problems like macular degeneration. The goal was to find out if the software helps doctors see and diagnose eye diseases more clearly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AngioScan angiography software (used with an FDA-approved OCT camera)
What this could lead to: If successful, this software could help doctors get clearer images of the eye, potentially leading to better diagnosis and treatment of retinal diseases.
What could go wrong: The software is not yet FDA-approved, and the study was terminated early, so results may be limited. It is a small, early-stage imaging study, not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration retinal vascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR DEGENERATION RETINAL VASCULAR DISORDER

Contacts and locations

Locations

Stein Eye Institute/Geffen School of Medicine

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.